A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population. [electronic resource]
Producer: 20021217Description: 606-13 p. digitalISSN:- 0923-7534
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carcinoma, Renal Cell -- drug therapy
- Drug Administration Schedule
- Female
- Humans
- Interferon alpha-2
- Interferon-alpha -- administration & dosage
- Interleukin-2 -- administration & dosage
- Kidney Neoplasms -- drug therapy
- Male
- Middle Aged
- Recombinant Proteins
- Survival Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.